Horizon Discovery grants a multi-product use licence of its GS knockout CHO K1 cell line to NGM Bio
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it will license its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line to NGM Biopharmaceuticals, Inc. (NGM).
Horizon Discovery signs collaboration and licence agreement with Mammoth Biosciences
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, announced that it has signed a collaboration and licence agreement with Mammoth Biosciences to access Mammoth’s novel CRISPR platform and thereby facilitate delivery of a new generation of genetically engineered CHO cells for the production of biotherapeutics such as therapeutic…
Horizon Discovery introduces predesigned synthetic sgRNAs to streamline CRISPR gene editing workflows
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, has announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range. The sgRNAs, available individually or as library collections, expand the Company’s Edit-R gene engineering platform which provides a convenient and accessible approach to successful…
Horizon Discovery partners with the Human Protein Atlas
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, announced that it has entered into a partnership with The Human Protein Atlas (HPA).
Horizon Discovery divests animal models business to Envigo
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, today announces an agreement to divest the Group’s animal research models business unit to Envigo RMS LLC.
Horizon Discovery reaches integration milestone and launches new website
Horizon Discovery Group plc (LSE: HZD), a global leader in the application of gene editing and gene modulation for cell line engineering, today went live with a new website and ecommerce system, marking a significant milestone in the Company’s strategy to fully integrate all tools, technologies and services, including Dharmacon reagents, under the Horizon brand.
Horizon Discovery signs licence agreement with Glenmark Pharmaceuticals for GS knockout CHO cell line for manufacture of biotherapeutics
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase (GS) knockout Chinese Hamster Ovary (CHO) K1 cell line.
Batavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic
Batavia Biosciences announced that the company has signed a licence agreement to utilise Horizon Discovery’s GS knockout CHO K1 cell line expression system for the development of high yield antibody-expressing cell lines. Initially, Batavia will deploy the system for production of a potent Zika virus neutralizing antibody, working in collaboration with Vanderbilt University Medical Center (VUMC)…
Horizon Discovery collaborates with St George’s University Hospital and EMQN
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced it is collaborating with St George’s University Hospital, London, and the European Molecular Genetics Quality Network (EMQN), based within the Manchester Centre for Genomic Medicine at Saint Mary’s Hospital, to develop reference material for non-invasive prenatal testing (NIPT).
Horizon Discovery and Rutgers University to develop next generation gene editing technology
Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announces that it has entered into an exclusive strategic partnership with Rutgers, The State University of New Jersey (US), to develop and commercialise a novel gene editing technology, known as base editing.